Project Grant K99CA317730
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $252,023 on September 3, 2026, under the Cancer Research Manpower program (CFDA 93.398) to adapt an evidence-based goals-of-care communication intervention for adolescent and young adult cancer patients (ages 15–39). The project addresses poor end-of-life outcomes in this population, including high rates of futile aggressive care interventions in the final month of life and low hospice enrollment. Current...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $745,458 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test a digital intervention that uses patient portals to improve person-centered communication between cancer patients and oncology clinicians. The PERSON intervention comprises three automated, scalable components: a portal-enabled assessment tool (a 14-item questionnaire capturing patient information...
- The National Cancer Institute, under the Department of Health and Human Services National Institutes of Health, awarded The Trustees of Columbia University in the City of New York $630,089 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds research to characterize the molecular mechanisms by which the DNA translocase SMARCAL1 suppresses anti-tumor immune responses and to identify other DNA damage response factors that function analogously to...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $155,052 on December 25, 2025, under the Cancer Research Manpower program (CFDA 93.398) to conduct spatiotemporal resolution of niche and genomic co-evolution in brain-metastatic organotropism. The funded research develops pre-clinical models and conducts multi-modal single-cell and spatial genomics analyses to investigate the relationship between chromosomal instability and brain metastasis...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $105,232 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research dissecting mechanisms, novel therapies, and human correlates of metastatic reactivation from dormancy. The research employs spatial transcriptomics and whole-genome sequencing to characterize spatiotemporal dynamics of cancer cells and tumor microenvironment changes during...
- The National Cancer Institute awarded Sloan-Kettering Institute For Cancer Research $263,073 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research identifying genetic factors mediating alternative lengthening of telomeres (ALT) in cancer. The research targets ALT, a recombination-based telomere maintenance mechanism present in 10–15 percent of cancers, particularly sarcomas and gliomas. The investigator will conduct three aims: examining how chromatin...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $187,037 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support adolescent and young adult enrollment in oncology clinical trials through bridging national and local trial systems. Dr. Justine Kahn, an associate professor of pediatrics and clinical trialist at Columbia University Irving Medical Center and the Herbert Irving Comprehensive Cancer Center (an...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $140,400 on July 17, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop multimodal, interpretable artificial intelligence models that integrate digital pathology images and tumor genomic data to improve precision cancer diagnosis and treatment selection. The award funds a two-phase K99/R00 career development grant. During the K99 phase, the recipient will study multimodal self-supervised...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $747,660 on June 2, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct the RADIANT trial, which builds evidence for a scalable remote patient monitoring and integrative medicine intervention delivered via telemedicine to reduce hospital readmissions in medical oncology patients discharged to home. The trial addresses the 12-week readmission rate for cancer patients, which ranges...
- The National Institutes of Health National Cancer Institute awarded $689,865 to The Trustees of Columbia University in the City of New York on August 5, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop methodological tools and frameworks for cancer microbiome study design and analysis. The award funds development of a comprehensive toolset to address contamination and batch-effect challenges in tumor microbiome research. Specific deliverables include a new method to...
The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $140,364 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support the K99 phase of research developing cancer survivor hospitalization risk assessment through multimodal analysis of care manager–patient communications in managed long-term care settings. The project, "The CHAMP Study: Cancer Survivor Hospitalization Risk Assessment Through Multimodal Patient-Care Manager Communications in Managed Long-Term Care," leverages telephone conversations and vocal cues from routine care manager contacts with cancer survivors enrolled in managed long-term care at VNS Health to identify early indicators of preventable hospitalizations and emergency department visits. Managed long-term care provides coordinated, community-based services to Medicaid beneficiaries with chronic conditions, including cancer survivors; care managers (nurses or social workers) conduct regular telephone monitoring. Current risk prediction models rely on structured electronic health record data and clinical notes but do not systematically capture the rich information—symptom details, functional decline, psychosocial concerns, and non-verbal vocal cues—documented during care manager–patient phone calls. The project seeks to integrate this untapped communication data into early risk detection models, addressing the clinical priority and value-based payment metric of reducing preventable hospitalizations and emergency department utilization. The award covers the period from August 1, 2026, through July 31, 2028, with place of performance in New York, New York.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $140.4k | 7/28/26 |